For people with multiple sclerosis (MS), a higher burden of comorbidity is associated with worse clinical outcomes, according ...

Sanofi’s experimental drug for a form of multiple sclerosis delayed the progression of disability by nearly a third, ...

Curtin University researchers have trialed an online nutrition education program designed to help people with multiple ...

Patients will be able to get a 10 minute injection of the Roche drug, instead of an hours-long infusion. Novartis already has ...

Gaps in access to care persist for US patients with MS and impact HRQOL to a large extent. Improving access to care for patients with MS should be prioritized.

Available disease-modifying therapies can prevent relapses and relapse-associated worsening in people with multiple sclerosis by targeting autoimmunity through various mechanisms. However, these ...

Buyers returned to the stock market today after the Federal Reserve decided to cut short-term interest rates by half a point ...

A study has revealed significant therapeutic inertia in the treatment of women with multiple sclerosis (MS), highlighting gender disparities that could impact long-term health outcomes for women of ...

with Halozyme's ENHANZE® drug delivery technology for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) as a twice-a-year, approximately 10-minute ...

Teva Pharmaceutical Industries Limited’s TEVA stock has risen 72.5% so far this year compared with an increase of 17.9% for ...

New research presented today at ECTRIMS 2024 reveals that initiating monoclonal antibody therapy during childhood, rather than delaying treatment until early adulthood, significantly reduces long-term ...

"Those with the highest burden of comorbidity had over a 30% increased risk of having disability worsening," Salter said. "In ...